[go: up one dir, main page]

WO2010008244A3 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation Download PDF

Info

Publication number
WO2010008244A3
WO2010008244A3 PCT/KR2009/003969 KR2009003969W WO2010008244A3 WO 2010008244 A3 WO2010008244 A3 WO 2010008244A3 KR 2009003969 W KR2009003969 W KR 2009003969W WO 2010008244 A3 WO2010008244 A3 WO 2010008244A3
Authority
WO
WIPO (PCT)
Prior art keywords
complications
active ingredient
pharmacologically active
blood pressure
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/003969
Other languages
French (fr)
Korean (ko)
Other versions
WO2010008244A2 (en
Inventor
김성욱
전성수
구자성
김병하
이나영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanall Pharmaceutical Co Ltd
Original Assignee
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Pharmaceutical Co Ltd filed Critical Hanall Pharmaceutical Co Ltd
Publication of WO2010008244A2 publication Critical patent/WO2010008244A2/en
Publication of WO2010008244A3 publication Critical patent/WO2010008244A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a pharmaceutical preparation comprising a prerelease compartment that includes an angiotension-2 receptor antagonist as its pharmacologically active ingredient and a delay-release compartment that includes a beta adrenalin blocker as its pharmacologically active ingredient; the preparation of the present invention acts to maintain a uniform constant pressure and prevent complications, and in particular, enables holding blood pressure uniform during the risk period for complications, so that it has the advantage of being useful for hypertension patients with complications, patients requiring blood pressure suppression during sleep, etc., and of reducing adverse reactions caused by drug interactions.
PCT/KR2009/003969 2008-07-18 2009-07-17 Pharmaceutical preparation Ceased WO2010008244A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0069793 2008-07-18
KR20080069793 2008-07-18

Publications (2)

Publication Number Publication Date
WO2010008244A2 WO2010008244A2 (en) 2010-01-21
WO2010008244A3 true WO2010008244A3 (en) 2010-05-14

Family

ID=41550875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003969 Ceased WO2010008244A2 (en) 2008-07-18 2009-07-17 Pharmaceutical preparation

Country Status (1)

Country Link
WO (1) WO2010008244A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030718B (en) * 2015-08-18 2018-01-30 石家庄格瑞药业有限公司 A kind of Arotinolol Hydrochlorid preparation and preparation method thereof
CN105012246B (en) * 2015-08-19 2018-04-06 湖北博华农牧科技有限公司 A kind of nano zine oxide coating process
KR101750689B1 (en) * 2015-09-15 2017-06-26 주식회사 종근당 Pharmaceutical combination preparation
CN116887866A (en) 2020-12-03 2023-10-13 巴特尔纪念研究院 Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050000556A (en) * 2002-05-17 2005-01-05 노파르티스 아게 Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
KR100582347B1 (en) * 2004-12-30 2006-05-22 한미약품 주식회사 Combination preparation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and antihypertensive agent and preparation method thereof
KR20070078625A (en) * 2006-01-27 2007-08-01 씨제이 주식회사 Multiple unit type sustained release oral preparation and method for preparing same
KR20080032616A (en) * 2006-10-10 2008-04-15 한올제약주식회사 Complex preparations for the treatment of cardiovascular diseases using the time difference dosing principle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050000556A (en) * 2002-05-17 2005-01-05 노파르티스 아게 Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
KR100582347B1 (en) * 2004-12-30 2006-05-22 한미약품 주식회사 Combination preparation of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and antihypertensive agent and preparation method thereof
KR20070078625A (en) * 2006-01-27 2007-08-01 씨제이 주식회사 Multiple unit type sustained release oral preparation and method for preparing same
KR20080032616A (en) * 2006-10-10 2008-04-15 한올제약주식회사 Complex preparations for the treatment of cardiovascular diseases using the time difference dosing principle

Also Published As

Publication number Publication date
WO2010008244A2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
WO2010008244A3 (en) Pharmaceutical preparation
WO2012010966A3 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
PT2222669E (en) Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
WO2010141761A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2011157416A3 (en) Transdermal administration of memantine
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2009054423A1 (en) Oxadiazolidinedione compound
CL2013000768A1 (en) Pharmaceutical composition comprising a compound derived from (6s) -6- (2-hydroxy-2-methylpropyl) -6-phenyl-3 - {(1s) -1- [4- (2-oxo-1,2-dihydropyridine -4-yl) phenyl] ethyl} -1,3-oxazin-2-one and a second therapeutic agent; and its use to prevent or delay a disorder associated with diabetes mellitus 2 or impaired glucose tolerance.
WO2009088414A3 (en) Oral pharmaceutical dosage forms
PH12012501370B1 (en) Stabilized formulations containing anti-interleukin -6- receptor (il-6r) antibodies
WO2010043566A3 (en) Combination of an insulin and a glp-1 agonist
EP2559434A3 (en) Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
MX2011011829A (en) Composition for sustained drug delivery comprising geopolymeric binder.
WO2009004082A3 (en) Anticonvulsive pharmaceutical compositions
UA103025C2 (en) Solid pharmaceutical formulation with delayed release
MX359288B (en) Ivabradine hydrochloride form iv.
WO2012158030A3 (en) Drug delivery system
EP2746254A3 (en) Oxadiazole derivative active on sphingosine-1-phosphate (s1p)
WO2009125987A3 (en) Pharmaceutical formulation
TN2010000302A1 (en) Estradiol-containing drug delivery system
IL195062A0 (en) Process for the preparation of solid sterile active pharmaceutical ingredient
WO2009125944A3 (en) Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
WO2011028016A3 (en) Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09798147

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09798147

Country of ref document: EP

Kind code of ref document: A2